<DOC>
	<DOCNO>NCT01973439</DOCNO>
	<brief_summary>To compare plasma pharmacokinetic ( PK ) parameter q24h versus q12h dose abacavir HIV-1-infected infant child age 3 month 36 month The secondary objective PENTA15 : To compare plasma PK parameter q24h versus q12h dose lamivudine HIV-1-infected infant child age 3 month 36 month receive lamivudine combination abacavir To compare age-related difference PK parameter q24h versus q12h dose abacavir lamivudine infant child 3 age group ( ≥3 &lt; 12 month , ≥12 &lt; 24 month ≥24 &lt; 36 month ) To describe child family acceptability adherence q24h compare q12h dosage regimens abacavir lamivudine</brief_summary>
	<brief_title>PENTA15 : Pharmacokinetic Study Once Versus Twice Daily Abacavir HIV-1 Infected Children Aged 3 &lt; 36 Months</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>Infants child confirm presence HIV1 infection Infants child age 3 &lt; 36 month Parents/guardians able willing give write , informed consent Currently combination ART include Abacavir ( ABC ) oral solution without Lamivudine ( 3TC ) oral solution , least 12 week expect stay regimen least 12 week . HIV1 RNA viral load either ; suppress HIV1 RNA viral load ( i.e . &lt; 400 copies/ml ) nonsuppressed , low , HIV1 RNA viral load ( i.e . 40020 000 copies/ml ) . The nonsuppressed child stable decrease HIV1 RNA viral load prior study entry consider still gain benefit current regimen Stable rise CD4+ cell percent prior study entry expect fall within next 12 week . Intercurrent illness Receiving concomitant therapy except prophylactic antibiotic Abnormal renal liver function ( grade 3 )</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Abacavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>